Yangtze River Pharmaceutical will market eight Alvotech biosimilars in China, under the terms of an exclusive deal that has just been agreed with the Alvogen sister company. The agreement involves the Alvotech & CCHT Biopharmaceutical joint venture between Alvotech and Changchun High & New Technology Industries – founded in March 2019 – and provides for biosimilar candidates to be manufactured in a new Chinese facility being constructed in Changchun.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?